There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LivaNova (LIVN) and Albireo Pharma (ALBO) with bullish sentiments.
LivaNova (LIVN)
Robert W. Baird analyst Michael Polark maintained a Buy rating on LivaNova on March 25 and set a price target of $85.00. The company’s shares closed last Monday at $74.11.
According to TipRanks.com, Polark is a 3-star analyst with an average return of 8.1% and a 64.0% success rate. Polark covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Irhythm Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LivaNova with a $83.00 average price target.
See today’s analyst top recommended stocks >>
Albireo Pharma (ALBO)
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Albireo Pharma on March 25 and set a price target of $67.00. The company’s shares closed last Monday at $33.71.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 5.9% and a 50.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Intellia Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $74.33 average price target, which is an 114.0% upside from current levels. In a report issued on March 16, Wedbush also maintained a Buy rating on the stock with a $73.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
